Possible new pathway can overcome glioblastoma resistance

Glioblastoma, a lethal brain cancer, is one of the most resistant to available therapies and patients typically live approximately 15 months. Previous research has focused on the activation of the apoptosis, or cell death, pathway using therapeutic agents such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); however, the vast majority of these experiments have been stymied by resistance. Researchers have now identified a possible new pathway for targeted therapies.

Read the whole article on Science Daily

More from Science Daily